Noriko Koizumi
Direktor/Vorstandsmitglied bei SEED CO.,LTD.
Profil
Noriko Koizumi is an Independent Outside Director at Seed Co., Ltd., a Professor at Doshisha University, the Chief Scientific Officer at ActualEyes, Inc., and a Professor at Graduate School of Medicine Kyoto University.
She received her undergraduate and doctorate degrees from Kyoto Prefectural University of Medicine.
Aktive Positionen von Noriko Koizumi
| Unternehmen | Position | Beginn |
|---|---|---|
| SEED CO.,LTD. | Direktor/Vorstandsmitglied | 24.06.2022 |
| Doshisha University | Corporate Officer/Principal | 01.04.2010 |
| Graduate School of Medicine Kyoto University | Corporate Officer/Principal | 01.04.2015 |
ActualEyes, Inc.
 ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2018 |
Ausbildung von Noriko Koizumi
| Kyoto Prefectural University of Medicine | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SEED CO.,LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
ActualEyes, Inc.
ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka. | Technology Services |
